Ongoing clinical trials (registered in ClinicalTrials.gov) involving combinatorial PD-1/PD-L1 blockade therapy in recurrent/metastatic head and neck squamous cell carcinoma as of June 2018. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.